These MYCN-amplified retinoblastomas exhibit distinct molecular signatures and demonstrate a clinically aggressive phenotype, characterized by rapid tumor growth, earlier age of onset typically within the first year of life, increased metastatic risk, and poor cellular differentiation [1]. This evidence concerns the gene MYCN and retinoblastoma.